Prescient Therapeutics Yönetim
Yönetim kriter kontrolleri 3/4
Prescient Therapeutics CEO'su Steven Yatomi-Clarke, Feb2016 tarihinde atandı, in görev süresi 8.75 yıldır. in toplam yıllık tazminatı A$ 657.01K olup, şirket hissesi ve opsiyonları dahil olmak üzere 63% maaş ve 37% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.39% ine doğrudan sahiptir ve bu hisseler A$ 414.21K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 9.2 yıl ve 9.5 yıldır.
Anahtar bilgiler
Steven Yatomi-Clarke
İcra Kurulu Başkanı
AU$657.0k
Toplam tazminat
| CEO maaş yüzdesi | 63.0% |
| CEO görev süresi | 8.8yrs |
| CEO sahipliği | 1.4% |
| Yönetim ortalama görev süresi | 9.2yrs |
| Yönetim Kurulu ortalama görev süresi | 9.5yrs |
Son yönetim güncellemeleri
Recent updates
Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation
Jul 05
We Think Prescient Therapeutics (ASX:PTX) Can Afford To Drive Business Growth
Mar 12We're Not Very Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Rate
Nov 14Companies Like Prescient Therapeutics (ASX:PTX) Are In A Position To Invest In Growth
Aug 01Shareholders Would Not Be Objecting To Prescient Therapeutics Limited's (ASX:PTX) CEO Compensation And Here's Why
Nov 22Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation
Oct 19Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business
Jun 19Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business
Feb 27We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Prescient Therapeutics Limited's (ASX:PTX) CEO For Now
Nov 05We Think Prescient Therapeutics (ASX:PTX) Can Easily Afford To Drive Business Growth
Aug 26Prescient Therapeutics (ASX:PTX) Is In A Good Position To Deliver On Growth Plans
May 08Does Prescient Therapeutics' (ASX:PTX) CEO Salary Compare Well With The Performance Of The Company?
Jan 11
CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | AU$657k | AU$414k | -AU$8m |
| Mar 31 2024 | n/a | n/a | -AU$8m |
| Dec 31 2023 | n/a | n/a | -AU$8m |
| Sep 30 2023 | n/a | n/a | -AU$7m |
| Jun 30 2023 | AU$663k | AU$400k | -AU$7m |
| Mar 31 2023 | n/a | n/a | -AU$6m |
| Dec 31 2022 | n/a | n/a | -AU$5m |
| Sep 30 2022 | n/a | n/a | -AU$5m |
| Jun 30 2022 | AU$771k | AU$392k | -AU$5m |
| Mar 31 2022 | n/a | n/a | -AU$5m |
| Dec 31 2021 | n/a | n/a | -AU$5m |
| Sep 30 2021 | n/a | n/a | -AU$5m |
| Jun 30 2021 | AU$800k | AU$360k | -AU$4m |
| Mar 31 2021 | n/a | n/a | -AU$4m |
| Dec 31 2020 | n/a | n/a | -AU$3m |
| Sep 30 2020 | n/a | n/a | -AU$3m |
| Jun 30 2020 | AU$639k | AU$392k | -AU$3m |
| Mar 31 2020 | n/a | n/a | -AU$4m |
| Dec 31 2019 | n/a | n/a | -AU$4m |
| Sep 30 2019 | n/a | n/a | -AU$4m |
| Jun 30 2019 | AU$586k | AU$367k | -AU$4m |
| Mar 31 2019 | n/a | n/a | -AU$3m |
| Dec 31 2018 | n/a | n/a | -AU$3m |
| Sep 30 2018 | n/a | n/a | -AU$3m |
| Jun 30 2018 | AU$479k | AU$330k | -AU$3m |
Tazminat ve Piyasa: Steven 'nin toplam tazminatı ($USD 426.96K ), Australian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 297.98K ).
Tazminat ve Kazançlar: Steven 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Steven Yatomi-Clarke
8.8yrs
Görev süresi
AU$657,007
Tazminat
Mr. Steven Lee Yatomi-Clarke has been Chief Executive Officer and Managing Director of Prescient Therapeutics Limited since February 15, 2016. Mr. Yatomi-Clarke has been Director of Prescient Therapeutics...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| MD, CEO & Director | 8.8yrs | AU$657.01k | 1.39% A$ 414.2k | |
| CFO & Company Secretary | 9.8yrs | AU$158.40k | Veri yok | |
| Director of Clinical Affairs & Operations | less than a year | Veri yok | Veri yok | |
| Chief Medical Officer | 9.6yrs | AU$157.36k | Veri yok |
9.2yrs
Ortalama Görev Süresi
Deneyimli Yönetim: PTX 'un yönetim ekibi deneyimli ve deneyimlidir ( 9.2 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| MD, CEO & Director | 10yrs | AU$657.01k | 1.39% A$ 414.2k | |
| Independent Non-Executive Chairman | 10.4yrs | AU$97.96k | 0.027% A$ 8.1k | |
| Independent Non-Executive Director | 10yrs | AU$61.41k | 0.049% A$ 14.7k | |
| Chairman of Clinical Advisory Board | 13.4yrs | Veri yok | Veri yok | |
| Member of Clinical Advisory Board | 13.4yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 10.2yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 9yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 9yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 3.9yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 8.8yrs | Veri yok | Veri yok | |
| Non-Executive Director | 4.4yrs | AU$61.41k | Veri yok | |
| Member of Scientific Advisory Board | 4.3yrs | Veri yok | Veri yok |
9.5yrs
Ortalama Görev Süresi
Deneyimli Yönetim Kurulu: PTX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.5 yıldır).